DOCSLIB.ORG

Dose-Finding and Pharmacologic Study of Chronic Oral Idarubicin Therapy in Metastatic Breast Cancer Patients1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dose-Finding and Pharmacologic Study of Chronic Oral Idarubicin Therapy in Metastatic Breast Cancer Patients1 Vol. 6, 2279–2287, June 2000 Clinical Cancer Research 2279 Dose-finding and Pharmacologic Study of Chronic Oral Idarubicin Therapy in Metastatic Breast Cancer Patients1 Giuseppe Toffoli, Roberto Sorio, Paola Aita, observed between absolute neutrophil count at nadir and ؊؍ ؍ Diana Crivellari, Giuseppe Corona, IDA area under the curve (P 0.022; r 0.33), IDA Cmax ؍ ؊0.38), IDOL area under the curve (P؍ r ;0.0067 ؍ P) ؊؍ ؍ ؊؍ ,Alessandra Bearz, Isabel Robieux 0.0009; r 0.43), and IDOL Cmax (P 0.0016; r 0.41), Anna Maria Colussi, Franco Stocco, and respectively. By multivariate analysis, IDA C was the 2 max .(0.01 ؍ P ;0.14 ؍ Mauro Boiocchi strongest determinant for neutropenia (R2 Divisions of Experimental Oncology 1 [G. T., P. A., G. C., M. B.] Among the 21 patients evaluable for response, 3 (14.3%) had and Medical Oncology [R. S., D. C., A. B., I. R., A. M. C.], Centro di partial response (lasting 3, 6, and 8 months, respectively), Riferimento Oncologico, 33081 Aviano, and Pharmacia & Upjohn, and 6 (28.6%) had a complete arrest of disease progression 20152 Milan [F. S.], Italy (lasting 2–6 months). In conclusion, the MTD of this sched- ule is 10 mg/day and the DLTs are neutropenia and diar- ABSTRACT rhea. Tolerance was good, and the treatment is feasible as Oral idarubicin (IDA) is an active drug in metastatic home therapy. Some objective measurable responses were breast cancer, but its role in the management of this tumor documented in this group of anthracycline-pretreated pa- is yet not established completely. To investigate a new mo- tients. IDOL could have a role for the pharmacological dality of IDA administration, a dose-finding study was de- effect. Further evaluation of this schedule is warranted to signed with hyperfractionated doses. The purpose was to assess the activity and toxicity of prolonged oral IDA ad- determine the maximum tolerated dose (MTD), the dose- ministration. limiting toxicity (DLT), and the pharmacokinetics of this schedule. IDA was administered twice daily as outpatient INTRODUCTION therapy in cycles of 3 weeks followed by a 1-week rest. IDA3 is a DAU analogue that has achieved a clinical role Thirty-one patients with progressive metastatic breast can- in the treatment of some hematological malignancies (1–7). cer and pretreated with chemotherapy (including epirubicin Recently, IDA has been also proposed in the management of and doxorubicin) were enrolled. DLT was defined as G4 adult solid tumors (8–13). IDA is endowed with greater biolog- hematological toxicity or any other toxicity G3 or higher ical activity and lower cardiotoxicity than DAU (2). Our and (Bloom and Richardson grading). Inter- and intrapatient other in vitro studies have indicated that IDA is more effective dose increases were studied. Pharmacokinetics of IDA and than DAU in tumor cell lines displaying the multidrug-resistant its metabolite idarubicinol (IDOL) were evaluated. IDA dose phenotype, thus suggesting that IDA could be useful in circum- was increased from 2 mg/day to 10 mg/day, by steps of 1 venting multidrug resistance (3, 14). mg/day, with the larger dose given in the evening. MTD was IDA therapy generally is well tolerated. The main IDA reached at 10 mg/day. Overall, the therapy cycles were 69 adverse effect is myelosuppression. Gastrointestinal toxicity is (median/patient, 2; range, 1–6). DLTs were G4 neutropenia also common. This includes nausea, vomiting, and stomatitis of associated with leukopenia and thrombocytopenia in one different WHO grades, according to the IDA dose schedule patient and G3 diarrhea in another of the 5 patients in the 10 used. G1-G2 diarrhea occurs in ϳ10% of patients after a single mg/day cohort. The two patients developing DLT at the i.v. dose (10–15 mg/m2) and in 10–30% of patients after oral daily dose of 10 mg received a dose normalized for body administration (40–45 mg/m2; Ref. 9). surface of 6.85 and 5.65 mg/m2/day, respectively. We con- The pharmacokinetics of IDA have been evaluated in can- sidered 5.5 mg/m2/day to be the MTD. Other toxicities were cer patients after i.v. or oral administration (10, 15). IDA has a nausea, vomiting, neutropenia, and diarrhea, grades G1 to large volume of distribution, which probably indicates extensive G2. By univariate analysis, significant correlations were tissue accumulation. IDA is metabolized, mainly in the liver after oral administration, to IDOL (10). IDOL retains good cytotoxic activity in vitro (15). Variability in oral absorption has been reported both between patients and within the same patient (10). Received 12/30/99; revised 2/29/00; accepted 3/1/00. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 3 The abbreviations used are: IDA, idarubicin; DAU, daunorubicin; 1 Supported in part by a grant from the Ministry of Health (“Ricerca IDOL, idarubicinol (4-demethoxy-13-dihydrodaunorubicin); AUC, area Finalizzata” FSN 1997). under the curve; t1/2, half-life; MTD, maximum tolerated dose; FEC, 2 To whom requests for reprints should be addressed, at Centro di fluorouracil-epirubicin- cyclophosphamide; LVEF, left ventricular ejec- Riferimento Oncologico, Via Pedemontana Occidentale 12, 33081 Avi- tion fraction; ANC, absolute neutrophil count; DLT, dose-limiting tox- ano (PN), Italy. Phone: 39-0434-659300; Fax: 39-0434-659428; E-mail: icity; Cmax, maximum plasma concentration; CL, clearance; Vd, volume [email protected]. of distribution; P-gp, P-glycoprotein. Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2000 American Association for Cancer Research. 2280 Chronic Oral IDA IDA is the first anthracycline that can be given both p.o. vious treatments were 440 mg/m2 (range, 155–765 mg/m2) and i.v. Oral IDA has been used in advanced breast cancer (11, and 180 mg/m2 (range, 140–317 mg/m2), respectively. 16). However, the role of oral IDA in this tumor needs to be The patients should not have received chemotherapy and/or better clarified. The oral route is useful in palliative treatment of radiation within 4 weeks before IDA treatment and were not patients with poor venous access and may be particularly ap- receiving concurrent hormonal therapy. Patients with a history propriate for older patients (17). Oral IDA in solid tumors was of cardiac disease were excluded. Other inclusion/exclusion administered over 1, 3, or 5 days (9). However, as demonstrated criteria were: normal baseline (Ն50%) LVEF; life expectancy previously for other antineoplastic drugs (18, 19), the effective- of at least 8 weeks; Eastern Cooperative Oncology Group per- ness of IDA might improve by low-dose continuous exposure. formance status of 0, 1, or 2; WBC count Ն4,000/␮l; platelet Although IDA is not a typical cell cycle phase-specific drug, it count Ն150,000/␮l; ANC Ն2,000/␮l; bilirubin level Յ1.5 mg/ exerts some antitopoisomerase II activity (1). It has been dem- dl; aspartate aminotransferase level two times normal or lower, Յ onstrated that the commitment to cell killing by antitopoisomer- serum creatinine level 1.5 mg/dl, and creatinine clearance Ն ase II agents predominantly occurs in S-phase cells (20). There- 60 ml/min. Written informed consent was obtained before fore, prolonged treatments with this drug increase the number of study entry and the protocol was approved by the local Ethical cells exposed to the drug during the most chemosensitive phase Committee. of the cell cycle. The increased ratio of IDOL/IDA AUC after Pretreatment and Treatment Evaluation. Pretreatment oral compared with i.v. administration represents another ad- evaluation included history and physical examination, chest vantage of prolonged low-dose treatments because IDA and its X-ray, liver ultrasound, electrocardiogram, determination of resting baseline LVEF by echocardiography and computed to- metabolite can cooperate in determining cytotoxic effects. Fi- mography, total body Tcm bone scan when clinically indicated, nally, the long plasmatic t of IDA and the longer t of IDOL 1/2 1/2 full blood cell count, electrolytes, blood urea nitrogen, creati- (10) are pharmacological characteristics extremely favorable in nine clearance (24-h urinary collection), liver function tests, protracted oral drug administration. In fact, they reduce the prothrombin time-international normalized ratio (PT-INR), and fluctuations in the plasmatic concentrations of the drug, allow- partial thromboplastin time (PTT). Laboratory tests were per- ing cells to be exposed to steadier drug concentrations, as with formed on a weekly base. Toxicities were graded using the continuous i.v. infusion therapy. WHO criteria. The compliance to therapy was assessed through To investigate a simple modality of IDA administration weekly pill counts in addition to a patient diary and evaluation instead of the cumbersome and costly continuous i.v. infusion, was according to the criteria of Miller et al. (21). a dose escalation of oral IDA was devised. The drug was given Treatment Plan. IDA was provided by Pharmacia Up- p.o. in hyperfractionated doses over a long period of time with john (Milan, Italy) in powder oral capsules of 1 and 5 mg. Each the purpose of determining the MTD, toxicity profile, and therapy course was administered for 21 days every 28 days, The pharmacokinetics of IDA this schedule. starting dose of 1 mg was taken around either 8.30 a.m. or 8.30 p.m. In the subsequent cycles, the dose was increased by 1 PATIENTS AND METHODS mg/day (with the larger dose given in the evening) until disease progression, refusal, or DLT. The 1-mg capsule to be added was Patients. Thirty-one patients, ages 39–73 years, with given alternatively in the morning or in the evening.
Load more

Recommended publications
  • Idamycin PFS® Idarubicin Hydrochloride Injection
    Idamycin PFS® idarubicin hydrochloride injection Rx only FOR INTRAVENOUS USE ONLY WARNINGS 1. IDAMYCIN PFS Injection should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration. 2. As is the case with other anthracyclines the use of IDAMYCIN PFS can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have pre- existing cardiac disease. 3. As is usual with antileukemic agents, severe myelosuppression occurs when IDAMYCIN PFS is used at effective therapeutic doses. 4. It is recommended that IDAMYCIN PFS be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection. 5. Dosage should be reduced in patients with impaired hepatic or renal function. (See DOSAGE AND ADMINISTRATION.) DESCRIPTION IDAMYCIN PFS Injection contains idarubicin hydrochloride and is a sterile, semi- synthetic, preservative-free solution (PFS) antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride is 5, 12-Naphthacenedione, 9-acetyl-7-[(3- amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11- trihydroxyhydrochloride, (7S-cis). The structural formula is as follows: C26 H27 NO9 .HCL M.W. 533.96 1 Reference ID: 3668307 IDAMYCIN PFS is a sterile, red-orange, isotonic parenteral preservative-free solution, available in 5 mL (5 mg), 10 mL (10 mg) and 20 mL (20 mg) single-use-only vials.
    [Show full text]
  • Idarubicin.Pdf
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrIDARUBICIN idarubicin hydrochloride injection Preservative Free Solution, 1 mg/mL, intravenous injection Antineoplastic Agent Pfizer Canada ULC Date of Initial Authorization: 17,300 Trans-Canada Highway July 30, 2013 Kirkland, Quebec, H9J 2M5 Date of Revision: September 14, 2021 Submission Control Number: 255782 ©Pfizer Canada ULC, 2021 IDARUBICIN (idarubicin hydrochloride injection) Page 1 of 31 RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, Cardiovascular JA/2021 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ..........................................................................................2 TABLE OF CONTENTS ............................................................................................................2 1 INDICATIONS.............................................................................................................4 1.1 Pediatrics .................................................................................................................4 1.2 Geriatrics..................................................................................................................4 2 CONTRAINDICATIONS................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...........................................................5 4 DOSAGE AND ADMINISTRATION................................................................................5
    [Show full text]
  • Summary Attachment for Eudract
    Avenue E. Mounier 83/11 1200 Brussels Belgium Tel: +32 2 774 1611 Email: [email protected] www.eortc.org Summary Attachment for EudraCT Name of Individual study Table Referring to Part of the Dossier (For National Authority Use Sponsor/Company: Only) EORTC Name of the Volume: finished product Name of Active Page Ingredients: Clofarabine Cytarabine Idarubicin Title of the Study Clofarabine in combination with a standard remissioninduction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) : a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial) Investigators & Study Centers Number of Country City patients Belgium 4 101.Hopital Jules Bordet (BE) Brussels 1 109.A.Z. St Jan (BE) Brugge 3 Italy 28 3931.Tor Vergata Roma (IT) Roma 12 733.La Sapienza Ematologia (IT) Roma 16 Netherlands 43 304.RU Nijmegen (NL) Nijmegen 24 310.Univ Med Ctr Leiden (NL) Leiden 13 22.J Bosch 'S Hertogenb (NL) 's-Hertogenbosch 6 Grand Total 75 ST-006-AF-01 Page 1 of 4 Template version 2 Short Study Report for Health Authorities EORTC Name of Individual study Table Referring to Part of the Dossier (For National Authority Use Sponsor/Company: Only) EORTC Name of the Volume: finished product Name of Active Page Ingredients: Clofarabine Cytarabine Idarubicin Publication Willemze R, Suciu S, Muus P, Halkes CJ, Meloni G, Meert L, Karrasch M, Rapion J, (reference) Vignetti M, Amadori S, de Witte T, Marie JP.Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • How I Treat How I Treat Hyperleukocytosis in Acute Myeloid Leukemia
    From www.bloodjournal.org by guest on January 2, 2016. For personal use only. How I Treat How I treat hyperleukocytosis in acute myeloid leukemia Christoph R¨olligand Gerhard Ehninger Medizinische Klinik und Poliklinik I, Universit¨atsklinikumder Technischen Universit¨at Dresden, Germany Hyperleukocytosis (HL) per se is a labora- chronic leukemias, and particularly leuko- lactate dehydrogenase as an indicator for tory abnormality, commonly defined by stasis occurs more often in acute myeloid high proliferation are part of prognostic a white blood cell count >100 000/mL, leukemia (AML) for several reasons. Only scores guiding risk-adapted consolidation caused by leukemic cell proliferation. Not a small proportion of AML patients present strategies, HL at initial diagnosis must be the high blood count itself, but complica- with HL, but these patients have a partic- considered a hematologic emergency and tions such as leukostasis, tumor lysis syn- ularly dismal prognosis because of (1) a requires rapid action of the admitting drome, and disseminated intravascular higher risk of early death resulting from physician in order to prevent early death. coagulation put the patient at risk and HL complications; and (2) a higher proba- (Blood. 2015;125(21):3246-3252) require therapeutic intervention. The risk bility of relapse and death in the long run. of complications is higher in acute than in Whereas initial high blood counts and high Incidence and pathophysiology In untreated acute myeloid leukemia (AML), ;5% to 20% of patients factor VII.18 TLS may occur as a result of spontaneous or treatment- present with hyperleukocytosis (HL).1-10 In a patient with HL, under- induced cell death.
    [Show full text]
  • Acute Lymphoblastic Leukemia (ALL) (Part 1 Of
    LEUKEMIA TREATMENT REGIMENS: Acute Lymphoblastic Leukemia (ALL) (Part 1 of 12) Note: The National Comprehensive Cancer Network (NCCN) Guidelines® for Acute Lymphoblastic Leukemia (ALL) should be consulted for the management of patients with lymphoblastic lymphoma. Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. They are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any
    [Show full text]
  • (Idarubicin) with Pharmacokinetic and in Vitro Drug Sensitivity Testing in Children with Refractory Leukemia1
    (CANCER RESEARCH 48, 5348-5352. September 15. 1988] Phase I Clinical Trial of Orally Administered 4-Demethoxydaunorubicin (Idarubicin) with Pharmacokinetic and in Vitro Drug Sensitivity Testing in Children with Refractory Leukemia1 Ching-Hon Pui,2 Siebold S. N. de Graaf,3 Lois W. Dow, John H. Rodman, William E. Evans, Bruce S. Alpert, and Sharon B. Murphy Departments ofHematology and Oncology [C-H. P., L. W. D., S. B. M.] and Pharmaceutical Division [S. S. N. d. G., J. H. R., W. E. E.], St. Jude Children's Research Hospital, and Divisions of Hematology-Oncology [C-H. P., L. W. D., S. B. M.] and Cardiology [B. S. A.], Department of Pediatrics, University of Tennessee, Memphis, College of Medicine, Memphis, Tennessee 38101 ABSTRACT than that of analogues or i.v. idarubicin (9, 16). However, nausea and vomiting were generally more severe in patients Fifteen children with acute leukemia in relapse, refractory to conven receiving oral idarubicin (16). As a single agent in adults, oral tional therapy, were treated with idarubicin administered orally for 3 consecutive days in dosages ranging from 30 to 50 mg/m2 per day at 19- idarubicin has antileukemic activity at dosages of 45 to 90 mg/ m2 distributed over 3 consecutive days (9, 17, 18). Very little to 21-day intervals. Gastrointestinal complications, including nausea, vomiting, abdominal pain, diarrhea and stomatitis, were the major forms information is available for oral idarubicin treatment in children of dose-limiting toxicity, affecting the majority of patients at all levels of with leukemia. We report here the results of Phase I clinical, idarubicin dosage.
    [Show full text]
  • S4 Acute Myeloid Leukaemia
    Haematology Cancer Clinical Guidelines Haematology Expert Advisory Group (EAG) on behalf of Northern Cancer Alliance Title: Haematology Cancer Clinical Guidelines Authors: Haematology EAG Circulation List: As detailed on page 2 Contact Details: Mrs C McNeill, Senior Administrator, Cancer Alliance Telephone: 01138252976 Version History: Date: 10.04.18 Version: V17-section 4 Review Date: November 2019 Document Control Version Date Summary Review Date V17 Date Agreed: Haematology EAG members agreed the Guidelines on: Emailed to group on 12.04.18, for formal endorsement at the next meeting. Review Date: November 2019 1 CONTENTS SECTION 1 NEHODS- Northern England Haemato- Diagnostic Service SECTION 2 Guidelines for Cytogenetic analysis in Haematological Malignancies SECTION 3 North of England Cancer Network Guidelines and Indications for PETCT SECTION 4 Guidelines for management of Acute Myeloid Leukaemia (AML) SECTION 5 Guidelines for Management of Myelodysplastic Syndromes SECTION 6 Guidelines for Management of Acute Lymphoblastic Leukaemia SECTION 7 Guidelines for the Management of Chronic Myeloid Leukaemia SECTION 8 Guidelines for Management of Myeloproliferative Disorders Polycythaemia Vera (PRV) Myelofibrosis (MF) SECTION 9 Guidelines for Management of Chronic Lymphocytic Leukaemia (CLL) and Lymphoproliferative Disorders Hairy Cell Leukaemia T-Prolymphocytic Leukaemia Waldenstrom Macroglobulinaemia SECTION 10 Guidelines for the Management of Low-grade Non-Hodgkin Lymphoma Mantle Cell Lymphoma SECTION 11 Guidelines for the Management
    [Show full text]
  • CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS
    CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS1 CYTOTOXIC HAZARDOUS MEDICATIONS NON-CYTOTOXIC HAZARDOUS MEDICATIONS Altretamine IDArubicin Acitretin Iloprost Amsacrine Ifosfamide Aldesleukin Imatinib 3 Arsenic Irinotecan Alitretinoin Interferons Asparaginase Lenalidomide Anastrazole 3 ISOtretinoin azaCITIDine Lomustine Ambrisentan Leflunomide 3 azaTHIOprine 3 Mechlorethamine Bacillus Calmette Guerin 2 Letrozole 3 Bleomycin Melphalan (bladder instillation only) Leuprolide Bortezomib Mercaptopurine Bexarotene Megestrol 3 Busulfan 3 Methotrexate Bicalutamide 3 Methacholine Capecitabine 3 MitoMYcin Bosentan MethylTESTOSTERone CARBOplatin MitoXANtrone Buserelin Mifepristone Carmustine Nelarabine Cetrorelix Misoprostol Chlorambucil Oxaliplatin Choriogonadotropin alfa Mitotane CISplatin PACLitaxel Cidofovir Mycophenolate mofetil Cladribine Pegasparaginase ClomiPHENE Nafarelin Clofarabine PEMEtrexed Colchicine 3 Nilutamide 3 Cyclophosphamide Pentostatin cycloSPORINE Oxandrolone 3 Cytarabine Procarbazine3 Cyproterone Pentamidine (Aerosol only) Dacarbazine Raltitrexed Dienestrol Podofilox DACTINomycin SORAfenib Dinoprostone 3 Podophyllum resin DAUNOrubicin Streptozocin Dutasteride Raloxifene 3 Dexrazoxane SUNItinib Erlotinib 3 Ribavirin DOCEtaxel Temozolomide Everolimus Sirolimus DOXOrubicin Temsirolimus Exemestane 3 Tacrolimus Epirubicin Teniposide Finasteride 3 Tamoxifen 3 Estramustine Thalidomide Fluoxymesterone 3 Testosterone Etoposide Thioguanine Flutamide 3 Tretinoin Floxuridine Thiotepa Foscarnet Trifluridine Flucytosine Topotecan Fulvestrant
    [Show full text]
  • Acute Myeloid Leukemia (AML) Treatment Regimens
    Acute Myeloid Leukemia (AML) Treatment Regimens Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. uInduction Therapy1 Note: All recommendations are Category 2A unless otherwise indicated. The NCCN believes the best option for any patient with cancer is in a clinical trial and strongly encourages this option for all patients. PATIENT CRITERIA REGIMEN AND DOSING Age <60 years2-8 Days 1–3: An anthracycline (daunorubicin 60–90mg/m2 IV OR idarubicin 12mg/m2) Days 1–7: Cytarabine 100–200mg/m2 continuous IV (Category 1).
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
    cells Review Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? Jan Philipp Bewersdorf and Amer M. Zeidan * Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, PO Box 208028, New Haven, CT 06520-8028, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-203-737-7103; Fax: +1-203-785-7232 Received: 19 September 2020; Accepted: 15 October 2020; Published: 17 October 2020 Abstract: Up to 18% of patients with acute myeloid leukemia (AML) present with a white blood cell (WBC) count of greater than 100,000/µL, a condition that is frequently referred to as hyperleukocytosis. Hyperleukocytosis has been associated with an adverse prognosis and a higher incidence of life-threatening complications such as leukostasis, disseminated intravascular coagulation (DIC), and tumor lysis syndrome (TLS). The molecular processes underlying hyperleukocytosis have not been fully elucidated yet. However, the interactions between leukemic blasts and endothelial cells leading to leukostasis and DIC as well as the processes in the bone marrow microenvironment leading to the massive entry of leukemic blasts into the peripheral blood are becoming increasingly understood. Leukemic blasts interact with endothelial cells via cell adhesion molecules such as various members of the selectin family which are upregulated via inflammatory cytokines released by leukemic blasts. Besides their role in the development of leukostasis, cell adhesion molecules have also been implicated in leukemic stem cell survival and chemotherapy resistance and can be therapeutically targeted with specific inhibitors such as plerixafor or GMI-1271 (uproleselan).
    [Show full text]